

National Cancer Center - Japan

Established by the Ministry of Health and Welfare in 1962, the National Cancer Center (NCC) leads the nation's cancer treatment, prevention, control programs, research and education. Dr Hitoshi Nakagama, the President leads the workforce of over 4000.

The leadership participates in and leads expert bodies appointed by the Ministry of Health, Labour and Welfare in the fight against cancer, most recently driving whole genome sequencing and gearing up drug development. Expertise is shared with the medical profession globally, with a focus on Asia. In 2010, it was designated an incorporated administrative agency (autonomous public service body), and then a national research and development agency in 2015, respectively remaining under the auspices of the Ministry of Health, Labour and Welfare.

<Organization>

Hospital and Hospital East (NCCH, NCCHE)

The two hospitals are national leaders in cancer treatment, offering specialized and comprehensive clinical services to cancer patients. Together, beds total 1000, with 350+ permanent physicians and 1200 nurses. Respectively, the locations are Tsukiji, Tokyo and Kashiwa, Chiba.

Research Institute (NCCRI)

Elucidates the etiology of cancer, utilizing genomic, epigenetic, proteomic and metabolomic analysis of tumor cells, collaborating with experts both within and external, to develop new treatments and advance genomic medicine. It is the largest cancer research center in Japan with over 350 professionals. The approach includes whole genome sequencing and analysis, RNA splicing aberrations, synthetic lethality, drug resistance mechanisms, biomarker identification, treatment systems utilizing AI, and drug development. The team also leverages its vast bioresource library to support drug development.

Exploratory Oncology Research and Clinical Trial Center (NCC EPOC)

Serves as a core of innovation for translational research, bridging the gap between preclinical and clinical research, working with the research institute and both hospitals.

Institute for Cancer Control (NCCICC)

Conducts epidemiological and interdisciplinary research towards the extension of healthy life spans. Specialists on prevention, screening, implementation, survivorship health economics, and global medicine cover research to policy advocacy. Information dissemination on cancer, support for the national network of 450+ designated cancer care hospitals, the national/hospital based cancer registries, and various cohorts are part of its portfolio.

Center for Cancer Genomics and Advanced Therapeutics (NCC C-CAT)

Collects and stores genome sequence data and clinical information nationwide, accrued into a knowledge database for cancer genomic medicine, generating reports for patients, as well as providing a research platform.

<Overseas Partners>

The Center works closely with IARC (International Agency for Research on Cancer) and other international organizations on WHO initiatives.

Memoranda of understanding are concluded with the following (in order of conclusion):

National Cancer Institute USA, Massachusetts General Hospital, INCa (Insitut National du Cancer), China-Japan Friendship Hospital, National Cancer Center PRC, National Cancer Center Korea, Dharmais Cancer Hospital Indonesia, National Cancer Hospital Vietnam, National Cancer Institute Thailand, Vital Strategies USA, Ho Chi Minh City Oncology Hospital, Tata Memorial Centre India, Ramathibodi Hospital Thailand, National Taiwan University Hospital